Nuwellis Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Nuwellis de 41.4% y 9% respectivamente, mientras que el BPA crecerá en un 130.7% al año.

Información clave

41.4%

Tasa de crecimiento de los beneficios

130.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.6%
Tasa de crecimiento de los ingresos	9.0%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	08 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Nuwellis hires Lynn Blake as CFO

Oct 19

Nuwellis surges 90% on positive data from Postoperative Coronary Artery Bypass Grafting treatment

Aug 31

Nuwellis Q2 2022 Earnings Preview

Aug 08

CHF Solutions down 10% on Q3 miss

Nov 10

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:NUWE - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	10	-10	N/A	N/A	1
12/31/2024	9	-10	N/A	N/A	1
3/31/2024	9	-20	-15	-15	N/A
12/31/2023	9	-23	-18	-18	N/A
9/30/2023	9	-17	-19	-18	N/A
6/30/2023	8	-17	-18	-18	N/A
3/31/2023	8	-17	-17	-16	N/A
12/31/2022	9	-15	-15	-15	N/A
9/30/2022	8	-17	-16	-16	N/A
6/30/2022	8	-18	-18	-17	N/A
3/31/2022	8	-19	-18	-17	N/A
12/31/2021	8	-20	-18	-18	N/A
9/30/2021	8	-18	-17	-17	N/A
6/30/2021	8	-17	-17	-17	N/A
3/31/2021	8	-17	-17	-16	N/A
12/31/2020	7	-18	-17	-17	N/A
9/30/2020	7	-19	-17	-17	N/A
6/30/2020	6	-19	-17	-16	N/A
3/31/2020	6	-20	-17	-17	N/A
12/31/2019	6	-23	-17	-16	N/A
9/30/2019	6	-22	-16	-15	N/A
6/30/2019	6	-22	-15	-15	N/A
3/31/2019	5	-22	-15	-14	N/A
12/31/2018	5	-17	-15	-15	N/A
9/30/2018	4	-29	-15	-15	N/A
6/30/2018	4	-27	-15	-15	N/A
3/31/2018	4	-27	-16	-15	N/A
12/31/2017	4	-25	N/A	-12	N/A
9/30/2017	3	-14	N/A	-11	N/A
6/30/2017	3	-15	N/A	-13	N/A
3/31/2017	2	-16	N/A	-12	N/A
12/31/2016	1	-18	N/A	-16	N/A
9/30/2016	1	-19	N/A	-18	N/A
6/30/2016	N/A	-22	N/A	-19	N/A
3/31/2016	N/A	-24	N/A	-22	N/A
12/31/2015	0	-27	N/A	-23	N/A
9/30/2015	0	-27	N/A	-24	N/A
6/30/2015	0	-26	N/A	-24	N/A
3/31/2015	0	-26	N/A	-23	N/A
12/31/2014	0	-26	N/A	-23	N/A
9/30/2014	0	-26	N/A	-23	N/A
6/30/2014	0	-26	N/A	-22	N/A
3/31/2014	0	-24	N/A	-20	N/A
12/31/2013	0	-22	N/A	-17	N/A
9/30/2013	0	-19	N/A	-15	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que NUWE siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que NUWE siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que NUWE siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (9% al año) de NUWE crezcan más rápidamente que los del mercado US (8.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 9% al año) de NUWE crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de NUWE se prevé que sea elevada dentro de 3 años.

Nuwellis Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates upgraded to US$2.69 loss

Price target decreased by 36% to US$6.00

Consensus revenue estimates fall by 19%

Price target decreased by 27% to US$16.00

Consensus EPS estimates upgraded to US$13.08 loss

Nuwellis, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Recent updates

Nuwellis Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Nuwellis, Inc. Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology

Nuwellis, Inc. to Report Q1, 2024 Results on May 07, 2024

Nuwellis, Inc. Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health

Consensus EPS estimates upgraded to US$2.69 loss

Nuwellis, Inc. Announces Results from Two New Clinical Data Analyses from the AVOID-HF Trial, Which Demonstrate the Benefits of its Aquadex System in Reducing Heart Failure Readmissions at 30 Days

Full year 2023 earnings: EPS exceeds analyst expectations

Nuwellis, Inc. to Report Q4, 2023 Results on Mar 05, 2024

New major risk - Share price stability

Nuwellis, Inc. Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter

Nuwellis Receives Non-Compliance Notice from Nasdaq

Nuwellis, Inc. Announces New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring Foriatric Patients

Price target decreased by 36% to US$6.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Less than half of directors are independent

Nuwellis, Inc. Announces Board of Directors Transition

Nuwellis, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Nuwellis, Inc. has completed a Composite Units Offering in the amount of $2.25 million.

Nuwellis Provides Regulatory Update on Seastar Medical's Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under A Humanitarian Device Exemption

New major risk - Share price stability

Nuwellis, Inc. Appoints Robert B. Scott as Chief Financial Officer, Effective September 2, 2023

Second quarter 2023 earnings released: US$3.65 loss per share (vs US$40.67 loss in 2Q 2022)

Nuwellis, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Revenue and earnings growth

Nuwellis, Inc. Announces the Appointment of Mike Mccormick to its Board of Directors

Consensus revenue estimates fall by 19%

Price target decreased by 27% to US$16.00

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$13.08 loss

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Nuwellis, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Nuwellis, Inc. Announces Board Changes

Nuwellis, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Nuwellis Appoints John Jefferies as Chief Medical Officer

Nuwellis Announces Compliance with Nasdaq Listing Requirements

Nuwellis, Inc. Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement

Price target decreased to US$2.17

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Nuwellis, Inc. Announces Peer Reviewed Data Demonstrating 71% Survival with Kidney Replacement Therapy Using A Modified Aquadex in Low-Birth-Weight Preterm Neonates

Insufficient new directors

Consensus forecasts updated

Nuwellis, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Nuwellis hires Lynn Blake as CFO

Nuwellis, Inc. Provides Product Revenue Guidance for the Three Months Ended September 30, 2022

Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality At the 2022 Hfsa Meeting

Insufficient new directors

Nuwellis, Inc. Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial

Nuwellis, Inc. Announces Executive Changes

Nuwellis, Inc. Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients

Nuwellis surges 90% on positive data from Postoperative Coronary Artery Bypass Grafting treatment

Nuwellis, Inc. Announces U.S. Patent and Trademark Office Awards Patent for Innovative Pediatric Technology

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Nuwellis Q2 2022 Earnings Preview

Nuwellis, Inc Announces the Submission of the AVOID-HF Clinical Analysis as a Late Breaking Clinical Trial at HFSA

Nuwellis, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Nuwellis, Inc. Announces First Patient Enrolled in Its Pivotal Trial REVERSE-HF

Nuwellis Receives a Letter from the Listing Qualifications Department of Nasdaq Regarding Minimum Bid Price Requirement

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$5.00

Nuwellis, Inc. to Report Q1, 2022 Results on May 10, 2022

Nuwellis, Inc., Annual General Meeting, May 17, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Nuwellis, Inc. Initiates REVERSE-HF Study to Evaluate Ultrafiltration for Heart Failure Patients with Fluid Overload

Nuwellis, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Price target decreased to US$8.67

Nuwellis, Inc. Provides Revenue Guidance for the Full Year 2021